Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI.
暂无分享,去创建一个
Samin K. Sharma | S. Pocock | M. Krucoff | G. Dangas | G. Weisz | D. Dudek | S. Mehta | R. Mehran | K. Huber | U. Baber | R. Kornowski | D. Cohen | C. Gibson | V. Kunadian | C. Briguori | D. Moliterno | S. Sartori | D. Cao | D. Angiolillo | J. Escaned | R. Gil | U. Kaul | E. Ohman | K. Oldroyd | G. Sardella | R. Shlofmitz | B. Witzenbichler | T. Collier | Zhongjie Zhang | D. Cohen | D. Cohen | C. Gibson
[1] D. Angiolillo,et al. Antithrombotic Management of Elderly Patients With Coronary Artery Disease. , 2021, JACC. Cardiovascular interventions.
[2] D. Angiolillo,et al. Ticagrelor or Clopidogrel in Elderly Patients with Myocardial Infarction: When the Choice Makes the Difference. , 2020, Circulation.
[3] B. Lindahl,et al. Comparison Between Ticagrelor and Clopidogrel in Elderly Patients With an Acute Coronary Syndrome , 2020, Circulation.
[4] Y. Jang,et al. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. , 2020, JAMA.
[5] M. Voskuil,et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial , 2020, The Lancet.
[6] L. Been,et al. Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study , 2020, Journal of the American Heart Association.
[7] M. Price,et al. Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score. , 2020, JACC. Cardiovascular interventions.
[8] Samin K. Sharma,et al. Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy. , 2020, Journal of the American College of Cardiology.
[9] P. Serruys,et al. Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD in Elderly Patients Aged Above 75 Years: a Prespecified Analysis of the Randomized GLOBAL LEADERS Trial. , 2019, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[10] S. James,et al. Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigms , 2019, Expert opinion on drug safety.
[11] Samin K. Sharma,et al. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. , 2019, The New England journal of medicine.
[12] D. Angiolillo,et al. Tailoring P2Y12 Inhibiting Therapy in Elderly Patients With Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention , 2019, Journal of the American Heart Association.
[13] L. Been,et al. Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus , 2019, JACC. Basic to translational science.
[14] W. Rottbauer,et al. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. , 2019, The New England journal of medicine.
[15] D. Angiolillo,et al. Aspirin for the primary prevention of cardiovascular disease: latest evidence , 2019, Expert review of cardiovascular therapy.
[16] Yong Hwan Park,et al. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial. , 2019, JAMA.
[17] H. Okayama,et al. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. , 2019, JAMA.
[18] M. Price,et al. Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention , 2019, Circulation.
[19] Francesca N. Delling,et al. Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association , 2019, Circulation.
[20] H. Pohlabeln,et al. Efficacy and Safety of Ticagrelor in Comparison to Clopidogrel in Elderly Patients With ST‐Segment–Elevation Myocardial Infarctions , 2019, Journal of the American Heart Association.
[21] G. Levine,et al. ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy: JACC Guideline Comparison. , 2018, Journal of the American College of Cardiology.
[22] F. Carreras,et al. P2Y12 antagonists and cardiac repair post-myocardial infarction: global and regional heart function analysis and molecular assessments in pigs , 2018, Cardiovascular research.
[23] Deepak L. Bhatt,et al. Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention , 2018, Nature Reviews Cardiology.
[24] S. de Servi,et al. Comparison of Reduced-Dose Prasugrel and Standard-Dose Clopidogrel in Elderly Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Revascularization , 2018, Circulation.
[25] S. Pocock,et al. Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. , 2016, American heart journal.
[26] E. Vicaut,et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial , 2016, The Lancet.
[27] G. Lip,et al. Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. , 2015, European heart journal.
[28] Peter L Duffy,et al. Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention. , 2015, Journal of the American College of Cardiology.
[29] D. Angiolillo,et al. Novel antiplatelet agents in acute coronary syndrome , 2015, Nature Reviews Cardiology.
[30] P. Armstrong,et al. Elderly Patients With Acute Coronary Syndromes Managed Without Revascularization: Insights Into the Safety of Long-Term Dual Antiplatelet Therapy With Reduced-Dose Prasugrel Versus Standard-Dose Clopidogrel , 2013, Circulation.
[31] T. Lindahl,et al. Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients. , 2013, Journal of the American College of Cardiology.
[32] C. Cannon,et al. Ticagrelor Versus Clopidogrel in Elderly Patients With Acute Coronary Syndromes: A Substudy From the Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLATO) Trial , 2012 .
[33] Junxiang Luo,et al. Relationship Between Exposure to Prasugrel Active Metabolite and Clinical Outcomes in the TRITON‐TIMI 38 Substudy , 2012, Journal of clinical pharmacology.
[34] D. Angiolillo,et al. Platelet function profiles in the elderly: Results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity , 2011, Thrombosis and Haemostasis.
[35] T. Warner,et al. Antiplatelet effects of aspirin vary with level of P2Y12 receptor blockade supplied by either ticagrelor or prasugrel , 2011, Journal of thrombosis and haemostasis : JTH.
[36] Marco Valgimigli,et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.
[37] J. Jakubowski,et al. In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation , 2011, Journal of thrombosis and haemostasis : JTH.
[38] Davide Capodanno,et al. Antithrombotic therapy in the elderly. , 2010, Journal of the American College of Cardiology.
[39] Claes Held,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.
[40] E. Antman,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.
[41] S. Hernández-Díaz,et al. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. , 2001, British journal of clinical pharmacology.